Summary: Although adjuvants are important components of vaccines, few studies have been conducted to establish the criteria on adjuvant selection and to investigate mechanisms of adjuvant actions during vaccination. Here we found that complete Freund adjuvant (CFA) induced a CD11b + cell population in a B-cell independent manner. This cell population exhibited strong ability to inhibit T-cellÀmediated rejection of tumor transplants. In vitro studies indicated that these cells induced T-cell apoptosis and down-regulated interferon-g production. Nitric oxide (NO) played important roles to achieve these effects. Plenty of NO was produced by these CFAinduced CD11b + cells. The addition of N G -nitro-L-arginine-methyl ester, an inhibitor of NO synthase, rescued T cells from apoptosis and partially abrogated the detrimental effects of CFA in cancer vaccines. Incomplete Freund adjuvant, one of the adjuvants still being used in clinical trials, also induced a similar cell population. Our results reveal a previously unknown mechanism in which the myeloid cell population induced by Freund adjuvant impairs antitumor immunity, and highlight the importance of adjuvant selection during tumor vaccination.
Summary: Although adjuvants are important components of vaccines, few studies have been conducted to establish the criteria on adjuvant selection and to investigate mechanisms of adjuvant actions during vaccination. Here we found that complete Freund adjuvant (CFA) induced a CD11b
+ cell population in a B-cell independent manner. This cell population exhibited strong ability to inhibit T-cellÀmediated rejection of tumor transplants. In vitro studies indicated that these cells induced T-cell apoptosis and down-regulated interferon-g production. Nitric oxide (NO) played important roles to achieve these effects. Plenty of NO was produced by these CFAinduced CD11b + cells. The addition of N G -nitro-L-arginine-methyl ester, an inhibitor of NO synthase, rescued T cells from apoptosis and partially abrogated the detrimental effects of CFA in cancer vaccines. Incomplete Freund adjuvant, one of the adjuvants still being used in clinical trials, also induced a similar cell population. Our results reveal a previously unknown mechanism in which the myeloid cell population induced by Freund adjuvant impairs antitumor immunity, and highlight the importance of adjuvant selection during tumor vaccination. T umor vaccines are promising to treat tumor patients for whom traditional treatments have failed. [1] [2] [3] Their low toxicity, tumor cell specificity, and the potential for persistence of the antitumor effect due to immunologic memory are positive attributes that justify the accelerated clinical development. [4] [5] [6] However, no current tumor vaccines have been demonstrated to reproducibly induce objective clinical response and reliable patient benefits. 7 In fact, much effort has been made to improve the efficacy of tumor vaccines. These efforts mainly focus on identifying appropriate tumor antigens, optimizing the interaction between antigenic peptides, antigen-presenting cells and T cells, or blocking tumor-induced immune inhibitory mechanisms. [8] [9] [10] [11] In contrast, adjuvant, as an important part of vaccines, receives little attention. Tumor antigens are derived from self proteins and are often less immunogenic. Potent immunostimulatory adjuvants are obviously required to induce robust T-cell responses. However, no criteria have been established about how to choose the optimum adjuvant at present. This situation results, at least partly, from our scarcity of knowledge on the acting mechanisms of adjuvants.
Emulsion adjuvants, including Freund adjuvant, are often used in experimental animals and, increasingly, in humans. 12 Recently, many clinical trials have used incomplete Freund adjuvant (IFA) as an adjuvant to enhance tumor vaccine efficacy. [13] [14] [15] [16] [17] [18] Complete Freund adjuvant (CFA) induces strong adverse toxicity and is unacceptable for use in human vaccines, but it is widely used in animal models, and is considered to be irreplaceable and vital for immunology research at the present time.
In the present study, we found that Freund adjuvant induced a population of myeloid cells, which inhibited the generation of protective antitumor immunity in some tumor models. The mechanism of this inhibition seemed to involve nitric oxide (NO)-mediated T-cell apoptosis as a NO synthase (NOS) inhibitor partially prevented the immune suppression due to the use of Freund adjuvants in tumor vaccines.
METHODS

Mice and Cell Lines
Female C57BL/6, BALB/c and 129/Sv/Ev mice (aged 6-8 wk) were obtained from Charles River (Sulzfeld, Germany) or Weitonglihua (Beijing, China). mMT mice have been previously described. 19 Sex-matched and agematched mice were used in all experiments. All mice were maintained in a specific pathogen-free barrier facility at the Institute of Biophysics, Chinese Academy of Sciences. Animal studies were conducted with the approval of the corresponding authorities.
MCA205 fibrosarcoma cells 20 were of C57BL/6 origin and J558L plasmacytoma cells 21 were of BALB/c origin. Both kinds of cells were cultured in RPMI 1640 (GIBCO, Grand Island, NY) supplemented with 10% fetal calf serum (GIBCO, Grand Island, NY), 100 units/mL penicillin, and 100 mg/mL streptomycin.
Cell Preparation and Culture
Whole splenocyte suspensions were prepared by mincing the spleens with scissors and teasing the tissue fragments between 2 frosted microscope slides. Cells suspended in media were then filtered through fine metal screens to remove cellular debris. Erythrocytes were lysed in erythrocyte lysis solution (155 mM NH 4 Cl, 10 mM KHCO 3 , and 0.1 mM ethylene diamine tetra-acetate, pH 7.4) for 1 to 2 minutes at room temperature. The cells were then washed in RPMI 1640 medium and cultured. For isolation of CD11b + cells, 5 to 6 Â 10 6 spleen cells suspended in phosphate-buffered saline (PBS) were incubated with 5 mg biotinylated anti-CD11b monoclonal antibody (mAb) for 15 minutes on ice. The cells were washed twice with cold PBS and then incubated with streptavidin microbeads for 15 minutes at 41C. The CD11b + cell population was isolated using MiniMACS columns (Miltenyi Biotec GmbH, Auburn, CA), and its purity, which was evaluated by flow cytometry, exceeded 90% (see Supplemental Figure, Supplemental Digital Content 1, http://links.lww.com/JIT/A19), which demonstrates the purity of isolated CD11b + cells. 
Adoptive Transfer of Antitumor Immunity
CD11b
+ cells were added. The CD11b + cells were isolated as described above from mice that had been injected with 0.1 mL CFA plus 0.1 mL PBS (CFA) or a mixture of 0.1 mL irradiated MCA205 tumor cell (5 Â 10 5 ) suspension and 0.1 mL CFA (MCA205/CFA). Tumor size was measured in millimeters using a caliper and was recorded as described previously. 22 
Immunization and Challenge
Exponentially growing MCA205 or J558L tumor cells were harvested, washed with PBS, and irradiated with 100 Gy of gamma radiation. Mice were SC immunized with 5 Â 10 5 irradiated MCA205 or 5 Â 10 6 irradiated J558L tumor cells suspended in 0.2 mL PBS or 0.1 mL PBS plus 0.1 mL CFA (MCA205/CFA or J558L/CFA), or just treated with 0.1 mL PBS plus 0.1 mL CFA (CFA) without the addition of irradiated tumor cells. Where indicated, mice were vaccinated with irradiated MCA205 tumor cells in 0.1 mL IFA emulsified with equal volumes of PBS (MCA205/IFA). To block NO production, vaccinated mice received 50 mg/kg/d of N G -nitro-L-arginine-methyl ester (L-NAME; Sigma-Aldrich, St. Louis, MO) at days 2 to 6 and 9 to 13 after immunization, whereas control mice received PBS injections. Two weeks later, all groups of mice were contralaterally SC challenged with 1 Â 10 5 MCA205
or 1 Â 10 6 J558L tumor cells. Tumor growth was monitored as described above.
Flow Cytometry Analysis
Single splenocyte suspensions were prepared as described above and stained with mAbs that were conjugated to fluorescein isothiocyanate, phycoerythrin, allophycocyanin, or peridinin chlorophyll protein, and were analyzed with a FACScalibur cytometer (BD Biosciences, San Diego, CA). For the 2-color immunofluorescence, mAbs were added according to the manufacturer's instructions. All of the antibodies used in flow cytometry were purchased from BD Pharmingen (San Diego, CA).
Cell Proliferation
Cell proliferation experiments were performed as previously described with slight modifications. 23 Briefly, 6 Â 10 6 splenocytes of naive mice were labeled with 2.5 mM carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes, Eugene, OR) for 10 minutes at 371C, and cultured with or without 1.2 Â 10 6 CD11b + cells from CFA-treated mice in the presence or absence of concanavalin A (Con A) (2.5 mg/mL) for 72 hours. Cells were then collected and stained with fluorescence-conjugated anti-CD4 and anti-CD8 mAbs.
Cell Viability Assay
Splenocytes of naive mice were plated on 96-well plate alone or together with CFA-induced CD11b + cells in the presence of Con A for 72 hours. Then 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was then added to the cell cultures. After 4 hours incubation at 371C, supernatants were discarded, and dimethyl sulfoxide was added to the wells to dissolve the purple crystal. Absorbance (OD) values were read at 495 nm. Results were recorded as relative ODs, which were calculated by dividing the absorbance data obtained from each culture by the absorbance data obtained from cultures without CD11b + cells.
Apoptosis Detection
Splenocytes from naive BALB/c or C57BL/6 mice were cultured in the presence of Con A, without or with the addition of splenic CD11b + cells isolated from CFA-treated mice at day 21. In some cultures, L-NAME (5 mM) was added to block iNOS activity. After 72 hours, cells were collected and stained with annexin V-fluorescein isothiocyanate and propidium iodide following the BD Pharmingen protocol and analyzed on FACS calibur cytometer.
Measurement of NO Production
For NO determination, supernatants of the cultures indicated above were collected, and assays were performed using the nitrate/nitrite colorimetric assay kit from Cayman Chemical Company. After converting nitrate in the culture supernatants to nitrite with nitrate reductase, Griess Reagents were added to convert nitrite into a deep purple compound. The absorbance at 550 nm was recorded with a microplate reader (Bio-Rad, Hercules, CA). Nitrite concentration was determined by comparing with the standards.
Cytokine Detection
Splenocytes were prepared from mice immunized with irradiated MCA205 cells, MCA205/CFA, CFA alone or PBS, and cultured in 24-well plate at a concentration of 2 Â 10 6 cells/mL in RPMI 1640 medium with the stimulation of irradiated MCA205 tumor cells at a ratio of 40:1. Three days later, interferon (IFN)-g in the culture supernatant was determined using enzyme-linked immunosorbent assay kits (BD Pharmingen) according to the manufacturer's instructions.
To determine the effect of CD11b + cells on IFN-g production, 2 Â 10 6 spleen cells isolated from MCA205-immunized mice were cocultured with CD11b + cells isolated from MCA205/CFA-treated mice (4 Â 10 5 or 1 Â 10 5 ) or isolated from CFA-treated mice (4 Â 10 5 ) and stimulated with irradiated MCA205 cells for 3, 5 and 7 days. Supernatants were collected and cytokines were determined.
Immunohistochemistry
Preparation of cryostat tissue sections and alkaline phosphatase immunostaining were carried out as described previously. 22, 24 Here, tumors were isolated 6 days after being challenged with viable MCA205 tumor cells from mice given different immunization treatments as described above. The mAbs used were anti-CD31 (MEC 13.3), anti-CD4 (GK1.5), and anti-CD8 (53 to 67).
For CD11b and Gr-1 staining, sections were incubated with anti-CD11b mAb (1:100, BD Pharmingen) or antiGr-1 mAb (1:100, BD Pharmingen), followed by incubation with biotinylated secondary antibody, and then Rhodamine-labeled streptavidin (for skin staining) or horseradish peroxidase-conjugated streptavidin (for spleen staining). The sections were then counterstained with Mayer's hematoxylin (Chroma Gesellschaft GmbH, Mu¨nster, Germany) or 4,6-Diamidino-2-phenylindole dihydrochloride hydrate (Sigma). Photographs were taken with a microscopic digital camera (DP71, Olympus, Tokyo, Japan).
Statistical Analysis
Data are expressed as means ± SD. Differences between experimental and control groups were assessed by 2-tailed unpaired Student t test. P values less than 0.05 were considered statistically significant. For survival studies, Kaplan-Meier survival curves were plotted and analyzed using MedCalc statistical software.
RESULTS
A CD11b
+ Myeloid Cell Population Is Induced by CFA
We have observed that a single injection of CFA in BALB/c mice led to nearly a 2-fold increase of total splenocyte number at day 21 (see Supplemental Figure, Supplemental Digital Content 2, http://links.lww.com/JIT/A20, which shows total splenocyte number after CFA treatment). Similar results were obtained in C57BL/6 mice (data not shown). When the splenocytes were analyzed, CD11b + cells were found to be partially responsible for the splenomegaly and this cell population expanded progressively after CFA treatment in both BALB/c and C57BL/6 mice ( Fig. 1A) . Further analysis showed that CFA-induced CD11b + cells did not express the lineage markers CD4, CD8, B220, and NK1.1 or DX5, suggesting that they were not T, B, or natural killer cells (data not shown). In addition, these cells showed no obvious changes in CD80 (B7-1), CD69, CD54 (intercellular adhesion molecule-1), CD106 (vascular cell adhesion molecule-1), and CD11c expression in comparison to CD11b + cells from PBS-treated control mice (Fig. 1B) . However, relative to their counterparts, CFA-induced CD11b + cells had a lower expression of the granulocyte marker Gr-1, macrophage marker F4/ 80, the class I major histocompatibility complex molecule H2-K d (BALB/c) or H2-K b (C57BL/6), and endothelial cell marker CD31 (Fig. 1B) . Similar results were obtained when 129/Sv/Ev mice were analyzed (see Supplemental Figure, Supplemental Digital Content 3, http://links.lww.com/JIT/ A21, which compares the expression of different cell surface markers as above).
Immunohistochemistry staining revealed that CFAinduced CD11b + or Gr-1 + cells were widely distributed in the red pulp, periarteriolar sheaths, subcapsular space, and interfollicular areas of the spleen in CFA-treated mice. In contrast, in PBS-treated mice, there were significantly fewer CD11b + or Gr-1 + cells distributed only in the interfollicular areas of the spleen (Fig. 1C and data not shown) . CD11b + and Gr-1 + cells also infiltrated heavily into the CFA injection site. As shown in Figure 1D , these cells clustered, surrounded the injected CFA emulsion and persisted even for a few months (see Supplemental Figure, Supplemental Digital Content 4, http://links.lww.com/JIT/A22, which shows the diameter of the nodule at indicated days and the staining result for the fibroblast marker ER-TR7).
A similar splenic myeloid cell population was also observed in mice after SC administration of IFA (Figs. 1E, F). The fact that these CD11b + myeloid cells can be induced by Freund adjuvant independent of host genetic background strongly indicates that they have important immune regulatory functions.
CD11b
+ Myeloid Cells Inhibit Immune Effector Cell-mediated Tumor Rejection + cells in the spleens of PBS-treated, IFA-treated, and CFA-treated mice), we used CFA-induced CD11b + cells in subsequent experiments. To determine whether these cells influence tumor rejection, we sorted CD11b + cells by using antiCD11b mAb from the spleens of mice treated with CFA alone or a mixture of irradiated MCA205 tumor cells and CFA (MCA205/CFA). Groups of C57BL/6 mice were SC inoculated with viable MCA205 cells. Twenty-four hours later, splenocytes isolated from MCA205-immunized mice, with or without the addition of various CD11b + cells, were IV transferred into these mice. Without immunotherapy, all mice died of tumors within about 30 days (data not shown). Adoptive transfer of MCA205-immunized spleen cells protected 60% of the mice from developing tumors (Fig. 2) . However, when CD11b + cells from CFA-treated or MCA205/CFA-treated mice were added to immune effector cells, the therapeutic efficacy was significantly impaired, with only 29% or 10% of the mice receiving protection (Fig. 2) . The difference between these 2 kinds of CD11b + cells is that the former developed in the absence of, whereas the latter developed in the presence of specific tumor antigens, namely, irradiated MCA205 cells. These results suggest that CFA-induced CD11b + cells could suppress immune effector cell-mediated tumor rejection.
The Generation of CD11b + Cells Is Independent of B Lymphocytes
It has been suggested that myeloid cells displaying high levels of the surface markers CD11b and Gr-1 induced by alum promote priming and expansion of antigen-specific B cells, 25 and our previous studies have shown that cytotoxic T lymphocyte-mediated antitumor immunity is impaired when B cells are present during the priming phase. 19 To determine whether B-cell presence is a prerequisite for the generation of CD11b + cells in this model, B-cellÀdeficient mMT mice were employed. A marked increase in both numbers and percentages of CD11b + cells was observed at day 21 after CFA treatment (Fig. 3A and data not shown) . Flow cytometric analysis revealed that in comparison to their counterparts, this population of cells was Gr-1 low , CD31 low , and MHC-I low (Fig. 3B) , similar to the CD11b + cells induced in wild-type mice (Fig. 1B) . These data indicate that the generation of CD11b + cells is independent of B cells.
CD11b + Cells Induce T-cell Apoptosis via NO
T lymphocytes are crucial effector cells against tumors. To determine whether CD11b + cells induced by CFA could directly suppress the proliferative response of T cells, splenocytes were labeled with CFSE and stimulated with Con A in the presence or absence of CD11b + cells isolated from the spleens of mice at day 21 after CFA treatment. Both BALB/c and C57BL/6 mice were analyzed. As shown in Figure 4A , CD11b + cells from CFA-treated mice did not significantly suppress the proliferation of either CD4 + or CD8 + T cells. However, a parallel experiment showed that the viability of splenocyte in cocultures containing CD11b + cells was significantly impaired in comparison to that of splenocytes cultured alone (Fig. 4B) . The decreased viability resulted, at least partly, from T-cell apoptosis, as annexin V and propidium iodide staining revealed a high ratio of T-cell apoptosis in the cocultures containing CD11b + cells (Fig.  4C) . Interestingly, addition of L-NAME, an inhibitor of NOS, to the cocultures reversed the apoptosis-inducing effect of CD11b + cells (Fig. 4C) . To confirm the hypothesis that NO produced by CD11b + cells was responsible for the enhanced apoptosis of Con A-activated splenocytes, we measured NO concentration in the cell cultures. As shown in Figure 4D , addition of CD11b + cells led to a significant increase of NO levels in the cultures of splenocytes from both BALB/c and C57BL/6 mice and this increase was almost completely eliminated by L-NAME. These data indicate that CD11b + cells induce T-cell apoptosis in an NO-dependent manner in vitro. Whether this is the case in vivo and whether other mechanisms exist require further investigation.
CD11b
+ Cells Downregulate IFN-c Production Next, we analyzed the effect of CD11b + cells on the production of IFN-g, one of the key cytokines produced primarily by hematopoietic cells and positively associated with tumor rejection. [26] [27] [28] [29] [30] Splenocytes were isolated from MCA205-immunized mice and stimulated with irradiated MCA205 tumor cells, with or without the addition of CD11b + cells isolated from mice immunized with CFA alone or MCA205/CFA. Splenocytes from MCA205-immunized mice generated large amounts of IFN-g at days 5 and 7 when cultured in the absence of CD11b + cells. However, when CD11b + cells were added, the IFN-gÀsecreting ability of immune splenocytes decreased markedly, no matter where the CD11b + cells were derived from (Fig. 4E) . The inhibition effect of CD11b + cells on IFN-g production by antigenstimulated splenocytes was very strong, as it could be observed not only at a ratio of 1:5 (CD11b + cells:splenocytes) but also at a ratio of 1:20 (Fig. 4E) . We also measured the production of interleukin (IL)-4, IL-10, and transforming growth factor-b in the culture supernatants of splenocytes with or without addition of CD11b + cells, and did not detect any significant differences (data not shown). These results show that CD11b + cells inhibit production of IFN-g, irrespective of whether they are induced by MCA205/CFA or CFA alone. ). IFN-g in the supernatants was determined by ELISA and expressed as means of triplicates ± SD. The IFN-g production by MCA205 cells alone control groups was below the detection limit (25 pg/mL). *P < 0.05. Data are representative of at least 3 independent experiments. CFA indicates complete Freund adjuvant; CFSE, carboxyfluorescein succinimidyl ester; Con A, concanavalin A; ELISA, enzyme-linked immunosorbent assay; IFN-g, interferon-g; L-NAME, N G -nitro-L-arginine-methyl ester; NO, nitric oxide; PI, propidium iodide.
Freund Adjuvant Impairs the Efficacy of Tumor Vaccines
To determine whether the addition of CD11b + cellsinducing adjuvants in tumor vaccines influences antitumor immunity, C57BL/6 mice were left untreated or were immunized with irradiated MCA205 tumor cells alone, CFA alone, or MCA205/CFA and were challenged 2 weeks later with viable MCA205 cells. Tumors grew rapidly in naive mice and killed the hosts within 40 days, whereas immunization with irradiated MCA205 cells protected 70% of the mice from tumor growth. However, if CFA was concurrently given with the same number of irradiated tumor cells, most of them (90%) failed to develop an expected immunologic resistance against the challenge of viable tumor cells. If CFA alone was administered to mice, the tumor cells inoculated secondarily were not rejected and all the mice were killed within 30 days (Fig. 5A) . To determine whether the detrimental effect of CD11b + cellsinducing adjuvants relies on the presence of B cells, mMT mice were immunized with irradiated J558L cells simultaneously with or without the addition of CFA and challenged 2 weeks later with a lethal dose of the same cells. Seven out of 9 mice immunized with irradiated tumor cells alone rejected the challenge tumor, whereas only 1 out of 9 mice received protection if CFA was used for the immunization (Fig. 5B) , indicating that the inhibitory function of CFA is independent of B cells. Similar results were obtained when IFA was used as an adjuvant (Fig. 5C ). These data show that both CFA and IFA have the ability to impair antitumor immunity when coinjected with tumor vaccines.
Consistent with the results above (Fig. 4E) , the ability of splenocytes from mice immunized with MCA205/CFA to produce IFN-g was severely impaired, whereas splenocytes derived from mice immunized with irradiated tumor cells alone produced high levels of IFN-g (Fig. 5D) , indicating that CFA impairs IFN-g production in vivo through inducing CD11b + cells. Our previous studies have shown that IFN-g derived from various immune cells inhibits tumor angiogenesis, subsequently leading to tumor rejection. 24, 31 Tumor-induced angiogenesis was investigated by staining tissue sections with an mAb against CD31, a marker on endothelial cells. As shown in Figure 5E , a large number of blood vessels were evenly distributed in tumors isolated from both PBS-treated and CFA-treated mice. In contrast, tumors isolated from MCA205-immunized mice were almost devoid of endothelial cells, and few CD31 + cells occurred at the rim of the tumor adjacent to neighboring tissue. The absence of blood vessels in the center of the tumors was accompanied by the appearance of large necrotic areas. Interestingly, multicentered small avascular areas formed in tumors isolated from mice immunized with MCA205/CFA were interlaced with vascularized regions. Subsequently, T-cell infiltration in the tumor site was analyzed. In MCA205/CFA-immunized mice, decreased CD8 + T lymphocyte infiltration was observed in comparison to that in MCA205-immunized mice (Fig. 5F ), indicating that CD11b + cells mainly influence CD8 + T lymphocytes.
Inhibition of NO Synthesis Partially Reverses CFA-mediated Suppression of Antitumor Immunity
As CD11b + cells induce T-cell apoptosis via NO (Fig. 4) , we wondered whether blockade of NO production would alleviate the detrimental effect of CFA in tumor vaccines. C57BL/6 mice were immunized with irradiated MCA205 cells or MCA205/CFA, treated with either PBS or L-NAME. Two weeks later, mice were challenged with viable MCA205 tumor cells. MCA205 vaccination protected the majority of mice from tumor growth, with about 8% of mice developing tumors, whereas CFA severely impaired this protection and 100% of the mice developed tumors. The application of L-NAME in vivo partially prevented the impairment on immune rejection and 67% of the mice developed tumors (Fig. 6) . Thus, L-NAME can prevent, at least in part, CFA-induced suppression of antitumor immunity.
DISCUSSION
Adjuvants are often used in clinical trials of tumor vaccines for the treatment of cancer patients. However, how adjuvants influence the therapeutic efficacy of vaccines is still not well understood. Here we show that CFA does not promote, but rather suppresses antitumor immunity in hosts by inducing a myeloid cell population. The adjuvantinduced myeloid cells impaired antitumor immunity during both the priming phase when the adjuvants and irradiated tumor cells were coinjected for immunization, and the effector phase when they were cotransferred with activated T cells into mice challenged by viable tumor cells. The impairment of antitumor immunity was consistently associated with and likely due to changes in the quantity and quality of CD8 + T cells as evidenced by increased apoptosis and decreased IFN-g production. This finding may help to explain the low therapeutic efficacy of cancer vaccines recently observed in some clinical trials using Freund adjuvant 18, 32 and underscores the necessity of selecting an appropriate adjuvant for active immunotherapy.
It is reported that pretreatment with CFA prevents the development of spontaneous autoimmune diseases, such as diabetes in nonobese diabetic mice, 33, 34 and the development of antigen-induced autoimmune disease, such as myelin oligodendrocyte glycoprotein -induced experimental allergic encephalomyelitis. 35 This protective effect was partially obtained by injection of the mycobacterium component alone, but was not observed on injection of IFA, 34 which is identical to CFA except for the absence of the mycobacterium component. Thus, mycobacterial components seem to be an important part of the protective effect of CFA. However, in the current study, we found that both CFA and IFA exhibited strong suppressive effects on antitumor immunity. As shown in Figure 5C , the addition of IFA completely abrogated the protective effect of irradiated MCA205 cells, as was the case when CFA was used. This finding indicates that these 2 adjuvants may also act by a common mechanism which is independent of mycobacterium.
The suppressive effect of CFA is clearly demonstrated in this study to be caused by the appearance and accumulation of CD11b + cells. These cells share some common features with previously observed tumor-induced myeloid-derived suppressor cells (MDSCs), [36] [37] [38] [39] [40] [41] [42] such as the expression of CD11b and Gr-1, production of high amounts of NO and suppressing antitumor immune responses. It is recently reported that the level of MDSCs in peripheral blood peaks at days 6 to 9 after CFA injection and returns to basal level by day 13. 43 However, in spleens of CFA-treated mice, the proportion of CD11b + cells was much higher than that in their counterparts at day 14 (Fig. 1A) In this study, CFA was shown to induce a small nodule at the injection site that persisted almost unchanged throughout the experimental period. Histologically, this nodule consisted of insoluble substances surrounded by interlaced fibers of collagen, and was infiltrated by large numbers of CD11b + or Gr-1 + cells, indicative of chronic inflammation. Given that tumors are essentially also a site of chronic inflammation and are described as ''wounds that will never heal,'' and that other conditions such as trauma, and infection also induce a similar MDSC population, [44] [45] [46] we suggest that the principal mechanism that causes the expansion of these myeloid cells is inflammation. This notion is supported by the observation that tumors with reduced inflammation exhibit a low accumulation of MDSCs 47, 48 and that this population of myeloid cells is greatly decreased in mice deficient of MyD88, a signal molecule that is well known to be essential for inflammatory reactions. 49 Our findings have important clinical implications. One important implication is that in vivo blockade of NO partially prevents the impairment of the protective effect induced by the adjuvant in the cancer vaccine. Interestingly, interrupting NO production in vitro also alleviates the detrimental effects of tumor-induced myeloid suppressive cells on T cells. [50] [51] [52] [53] The fact that L-NAME administration could rescue T-cell dysfunction and partially restore antitumor immunity points to a possible way for improving the efficacy of cancer vaccination. The myeloid suppressor cells, either induced by chemical drugs or expanded by cytokines, are reported to have the ability to improve graft acceptance and to suppress the initiation of graft-versushost disease. 42, 54, 55 Whether Freund adjuvant, as a strong inducer for the expansion of CD11b + cells, has therapeutic potential for organ transplantation should be further addressed.
It should be pointed out that the present study has several limitations. Many active clinical trials or closed clinical trials are using IFA, but not CFA, whereas we used mostly CFA rather than IFA to elucidate our point. Not unexpectedly, therefore, the experimental model differs in certain respects from its proposed natural human counterpart. However, using CFA as an example, the study wants to highlight the importance of adjuvant selection in tumor vaccines, and clinical investigators may be well advised to take a closer look at it as a possible reason for the low efficacy of tumor vaccines at this time.
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FIGURE 5.
Freund adjuvant impairs the efficacy of tumor vaccines via down-regulation of IFN-g production. A, Female C57BL/6 mice were left untreated (*, n = 6) or immunized with irradiated MCA205 tumor cells alone (, n = 10), CFA alone (D, n = 6) or MCA205/CFA (~, n = 10), and challenged 2 weeks later with viable MCA205 tumor cells. *P < 0.05. B, mMT mice were immunized with irradiated J558L tumor cells in the absence (', n = 9) or presence (&, n = 9) of CFA and challenged 2 weeks later with viable J558L tumor cells. Shown are combined data of 2 independent experiments. *P < 0.05. C, Female C57BL/6 mice were immunized with irradiated MCA205 tumor cells (, n = 5) or MCA205/IFA (~, n = 5) and challenged 2 weeks later with viable MCA205 tumor cells. *P < 0.05. D, Splenocytes from mice previously immunized with irradiated MCA205 tumor cells alone, CFA alone, MCA205/CFA or PBS were cultured for 72 hours with the stimulation of irradiated MCA205 cells. IFN-g in the supernatants was determined by ELISA. *P < 0.05. Data are expressed as the means of triplicate values ± SD, and are representative of 2 independent experiments. E, Tumor sections were prepared 6 days after challenging with viable MCA205 tumor cells from mice previously immunized as above, and then were stained with anti-CD31 mAb. Necrotic areas (N) are indicated by the dotted yellow lines. F, Tumor sections were prepared 6 days after challenging with viable MCA205 tumor cells from mice previously immunized by irradiated MCA205 cells or MCA205/CFA, and then stained with anti-CD4 or anti-CD8 mAb. Images are representative from at least 3 tumors per group. Bar graph representing the numbers of CD4 + or CD8 + T cells per group. *P < 0.05. Six independent fields/section were counted to obtain the representative value. CFA indicates complete Freund adjuvant; ELISA, enzyme-linked immunosorbent assay; IFN-g, interferon-g; mAB, monoclonal antibody; PBS, phosphate-buffered saline.
